TY - JOUR
T1 - Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis
AU - Kimura, Akio
AU - Takemura, Masao
AU - Serrero, Ginette
AU - Yoshikura, Nobuaki
AU - Hayashi, Yuichi
AU - Saito, Kuniaki
AU - Inuzuka, Takashi
N1 - Funding Information:
The authors would like to thank Dr. T. Kudo, Dr. M. Yasunishi, Dr. A. Takekoshi, Dr. N. Harada, Dr. A. Koumura and Dr. M. Yamada (Departments of Neurology and Geriatrics, Gifu University Graduate School of Medicine) for providing patients? clinical information. We also thank Marla Brunker, from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript. The authors declare that they have no conflict of interest.
Funding Information:
Funding This research was partially supported by a Grant-in-Aid for Scientific Research (C) (26461290) from the Japan Society for the Promotion of Science.
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
AB - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85042767843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042767843&partnerID=8YFLogxK
U2 - 10.1007/s11060-017-2742-z
DO - 10.1007/s11060-017-2742-z
M3 - Article
C2 - 29340960
AN - SCOPUS:85042767843
VL - 137
SP - 455
EP - 462
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 3
ER -